A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2) (NCT06496178)
A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Who can join: Review the eligibility criteria below.
Location: Site 160 — Mobile, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (218 Sites)
Showing the first 25 of 218 sites.
- Site 160 — Mobile, Alabama
- Site 102 — Prescott, Arizona
- Site 125 — Scottsdale, Arizona
- Site 82 — Duarte, California
- Site 25 — La Jolla, California
- Site 173 — Orange, California
- Site 28 — Palo Alto, California
- Site 127 — Sacramento, California
- Site 46 — San Francisco, California
- Site 130 — Lone Tree, Colorado
- Site 104 — Washington D.C., District of Columbia
- Site 12 — Fort Myers, Florida
- Site 123 — Jacksonville, Florida
- Site 9 — Orlando, Florida
- Site 138 — Tampa, Florida
- Site 187 — Atlanta, Georgia
- Site 207 — Atlanta, Georgia
- Site 152 — Chicago, Illinois
- Site 213 — Chicago, Illinois
- Site 68 — Chicago, Illinois
- Site 31 — Indianapolis, Indiana
- Site 8 — Louisville, Kentucky
- Site 40 — Baton Rouge, Louisiana
- Site 100 — New Orleans, Louisiana
- Site 153 — Columbia, Maryland
📞 Contact the Study Coordinator
Phone: (617) 401-4499
Email: USenquiries@merus.nl
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Head and Neck Squamous Cell Carcinoma
- Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Fullerton, California
- Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck — Duarte, California
- MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients — Gilbert, Arizona
- Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 — St Louis, Missouri
- Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic Head and Neck Cancer, The INSIGHT Trial — Buffalo, New York
- Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca — Baltimore, Maryland
Explore by condition: All Head and Neck Squamous Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.